Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?

Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?

Glioblastoma (GBM) is an aggressive and fatal malignancy that despite decades of trials has limited therapeutic options. Antibody drug conjugates (ADCs) are composed of a monoclonal antibody which specifically recognizes a cellular surface antigen linked to a cytotoxic payload. ADCs have demonstrate...

Full description

Bibliographic Details
Main Authors: Sagun Parakh, Joseph Nicolazzo, Andrew M Scott, Hui Kong Gan
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-12-01
Series:Frontiers in Oncology
Subjects:
antibody drug conjugates (ADC)
glioma
glioblastoma
blood brain barrier
tumour microenvironment
biomarkers
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.718590/full

Similar Items

Similar Items